Dr Yan Gong and colleagues evaluated the effects of Hepatitis B vaccine and immunoglobulin in newborn infants of mothers positive for Hepatitis B surface antigen.
The research team conducted a systematic review and meta-analysis of randomized clinical trials.
The team searched electronic databases and conducted hand searches of articles.
Randomized clinical trials were assessed for methodological quality.
Meta-analysis was undertaken on 3 outcomes.
The outcomes included the relative risks of Hepatitis B occurrence, antibody levels to Hepatitis B surface antigen, and adverse events.
The researchers identified 29 randomized clinical trials, 5 of which were considered high quality.
|Vaccine plus Hep B immunoglobulin reduced Hep B occurrence|
|British Medical Journal|
The team found that only 3 trials reported inclusion of mothers negative for Hepatitis B e antigen.
Compared with placebo or no intervention, vaccination reduced the occurrence of Hepatitis B.
No significant difference in Hepatitis B occurrence was found between recombinant vaccine and plasma derived vaccine.
The researchers observed no difference between high dose versus low dose vaccine.
Compared with placebo or no intervention, Hepatitis B immunoglobulin reduced Hepatitis B occurrence.
The team noted that the combination of plasma derived vaccine and Hepatitis B immunoglobulin also reduced Hepatitis B occurrence.
Compared with vaccine alone, vaccine plus Hepatitis B immunoglobulin reduced Hepatitis B occurrence.
Hepatitis B vaccine and Hepatitis B immunoglobulin seem safe, but few trials reported adverse events.
Dr Gong's team commented, “Hepatitis B vaccine, Hepatitis B immunoglobulin, and vaccine plus immunoglobulin prevent Hepatitis B occurrence in newborn infants of mothers positive for Hepatitis B surface antigen.”